A citation-based method for searching scientific literature

Gareth Hughes, Hannah Toellner, Helen Morris, Colm Leonard, Nazia Chaudhuri. J Clin Med 2016
Times Cited: 97







List of co-cited articles
578 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Luca Richeldi, Roland M du Bois, Ganesh Raghu, Arata Azuma, Kevin K Brown, Ulrich Costabel, Vincent Cottin, Kevin R Flaherty, David M Hansell, Yoshikazu Inoue,[...]. N Engl J Med 2014
59

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Talmadge E King, Williamson Z Bradford, Socorro Castro-Bernardini, Elizabeth A Fagan, Ian Glaspole, Marilyn K Glassberg, Eduard Gorina, Peter M Hopkins, David Kardatzke, Lisa Lancaster,[...]. N Engl J Med 2014
57

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
Ganesh Raghu, Harold R Collard, Jim J Egan, Fernando J Martinez, Juergen Behr, Kevin K Brown, Thomas V Colby, Jean-François Cordier, Kevin R Flaherty, Joseph A Lasky,[...]. Am J Respir Crit Care Med 2011
47

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Paul W Noble, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Marilyn K Glassberg, David Kardatzke, Talmadge E King, Lisa Lancaster, Steven A Sahn, Javier Szwarcberg,[...]. Lancet 2011
45

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.
Ganesh Raghu, Bram Rochwerg, Yuan Zhang, Carlos A Cuello Garcia, Arata Azuma, Juergen Behr, Jan L Brozek, Harold R Collard, William Cunningham, Sakae Homma,[...]. Am J Respir Crit Care Med 2015
37

Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions.
Jonathan A Galli, Aloknath Pandya, Michelle Vega-Olivo, Chandra Dass, Huaqing Zhao, Gerard J Criner. Respirology 2017
91
37

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
Luca Richeldi, Ulrich Costabel, Moises Selman, Dong Soon Kim, David M Hansell, Andrew G Nicholson, Kevin K Brown, Kevin R Flaherty, Paul W Noble, Ganesh Raghu,[...]. N Engl J Med 2011
663
32

Clinical course and prediction of survival in idiopathic pulmonary fibrosis.
Brett Ley, Harold R Collard, Talmadge E King. Am J Respir Crit Care Med 2011
914
28

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Ganesh Raghu, Martine Remy-Jardin, Jeffrey L Myers, Luca Richeldi, Christopher J Ryerson, David J Lederer, Juergen Behr, Vincent Cottin, Sonye K Danoff, Ferran Morell,[...]. Am J Respir Crit Care Med 2018
24

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.
Paul W Noble, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Roland M du Bois, Elizabeth A Fagan, Robert S Fishman, Ian Glaspole, Marilyn K Glassberg, Lisa Lancaster,[...]. Eur Respir J 2016
223
21

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Lutz Wollin, Eva Wex, Alexander Pautsch, Gisela Schnapp, Katrin E Hostettler, Susanne Stowasser, Martin Kolb. Eur Respir J 2015
379
20

Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis.
Francesco Bonella, Michael Kreuter, Lars Hagmeyer, Claus Neurohr, Claus Keller, Martin J Kohlhaeufl, Joachim Müller-Quernheim, Katrin Milger, Antje Prasse. Respiration 2016
41
46

Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS.
Ulrich Costabel, Yoshikazu Inoue, Luca Richeldi, Harold R Collard, Inga Tschoepe, Susanne Stowasser, Arata Azuma. Am J Respir Crit Care Med 2016
157
19

Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.
Luca Richeldi, Vincent Cottin, Roland M du Bois, Moisés Selman, Toshio Kimura, Zelie Bailes, Rozsa Schlenker-Herceg, Susanne Stowasser, Kevin K Brown. Respir Med 2016
223
19

Pirfenidone in idiopathic pulmonary fibrosis.
H Taniguchi, M Ebina, Y Kondoh, T Ogura, A Azuma, M Suga, Y Taguchi, H Takahashi, K Nakata, A Sato,[...]. Eur Respir J 2010
623
18

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis.
Tamera Corte, Francesco Bonella, Bruno Crestani, Maurits G Demedts, Luca Richeldi, Carl Coeck, Katy Pelling, Manuel Quaresma, Joseph A Lasky. Respir Res 2015
76
23

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.
Martin Kolb, Luca Richeldi, Jürgen Behr, Toby M Maher, Wenbo Tang, Susanne Stowasser, Christoph Hallmann, Roland M du Bois. Thorax 2017
121
17

Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
Eva Brunnemer, Julia Wälscher, Svenja Tenenbaum, Julia Hausmanns, Karen Schulze, Marianne Seiter, Claus Peter Heussel, Arne Warth, Felix J F Herth, Michael Kreuter. Respiration 2018
42
40

Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Ganesh Raghu, Kevin J Anstrom, Talmadge E King, Joseph A Lasky, Fernando J Martinez. N Engl J Med 2012
923
16

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.
Steven D Nathan, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Roland M du Bois, Elizabeth A Fagan, Robert S Fishman, Ian Glaspole, Marilyn K Glassberg, Kenneth F Glasscock,[...]. Thorax 2016
102
15

Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
Steven D Nathan, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Ian Glaspole, Marilyn K Glassberg, David R Kardatzke, Monica Daigl, Klaus-Uwe Kirchgaessler, Lisa H Lancaster,[...]. Lancet Respir Med 2017
151
15

Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study.
S Harari, A Caminati, C Albera, C Vancheri, V Poletti, A Pesci, F Luppi, C Saltini, C Agostini, E Bargagli,[...]. Respir Med 2015
57
26

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.
Harold R Collard, Christopher J Ryerson, Tamera J Corte, Gisli Jenkins, Yasuhiro Kondoh, David J Lederer, Joyce S Lee, Toby M Maher, Athol U Wells, Katerina M Antoniou,[...]. Am J Respir Crit Care Med 2016
588
14


Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.
Lisa Lancaster, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Roland M du Bois, Elizabeth A Fagan, Robert S Fishman, Ian Glaspole, Marilyn K Glassberg, Talmadge E King,[...]. BMJ Open Respir Res 2016
69
18

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
Frank Hilberg, Gerald J Roth, Martin Krssak, Susanna Kautschitsch, Wolfgang Sommergruber, Ulrike Tontsch-Grunt, Pilar Garin-Chesa, Gerd Bader, Andreas Zoephel, Jens Quant,[...]. Cancer Res 2008
704
13

Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry.
Jürgen Behr, Michael Kreuter, Marius M Hoeper, Hubert Wirtz, Jens Klotsche, Dirk Koschel, Stefan Andreas, Martin Claussen, Christian Grohé, Henrike Wilkens,[...]. Eur Respir J 2015
133
13

A multidimensional index and staging system for idiopathic pulmonary fibrosis.
Brett Ley, Christopher J Ryerson, Eric Vittinghoff, Jay H Ryu, Sara Tomassetti, Joyce S Lee, Venerino Poletti, Matteo Buccioli, Brett M Elicker, Kirk D Jones,[...]. Ann Intern Med 2012
626
12

Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review.
John Hutchinson, Andrew Fogarty, Richard Hubbard, Tricia McKeever. Eur Respir J 2015
367
12

Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres.
Hannah Toellner, G Hughes, W Beswick, M G Crooks, C Donaldson, I Forrest, S P Hart, C Leonard, M Major, A J Simpson,[...]. Clin Transl Med 2017
22
54

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.
Lisa H Lancaster, Joao A de Andrade, Joseph D Zibrak, Maria L Padilla, Carlo Albera, Steven D Nathan, Marlies S Wijsenbeek, John L Stauffer, Klaus-Uwe Kirchgaessler, Ulrich Costabel. Eur Respir Rev 2017
71
16

Clinical Experience of the Long-term Use of Pirfenidone for Idiopathic Pulmonary Fibrosis.
Masashi Bando, Hiroyoshi Yamauchi, Takashi Ogura, Hiroyuki Taniguchi, Kentaro Watanabe, Arata Azuma, Sakae Homma, Yukihiko Sugiyama. Intern Med 2016
33
33

Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases.
Ute Oltmanns, Nicolas Kahn, Karin Palmowski, Annette Träger, Heinrich Wenz, Claus Peter Heussel, Philipp A Schnabel, Michael Puderbach, Matthias Wiebel, Svenja Ehlers-Tenenbaum,[...]. Respiration 2014
68
16

Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function.
Carlo Albera, Ulrich Costabel, Elizabeth A Fagan, Marilyn K Glassberg, Eduard Gorina, Lisa Lancaster, David J Lederer, Steven D Nathan, Dominique Spirig, Jeff J Swigris. Eur Respir J 2016
92
11

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Arata Azuma, Toshihiro Nukiwa, Eiyasu Tsuboi, Moritaka Suga, Shosaku Abe, Koichiro Nakata, Yoshio Taguchi, Sonoko Nagai, Harumi Itoh, Motoharu Ohi,[...]. Am J Respir Crit Care Med 2005
629
11

Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice.
Ryo Okuda, Eri Hagiwara, Tomohisa Baba, Hideya Kitamura, Terufumi Kato, Takashi Ogura. Respir Med 2013
69
15

Idiopathic Pulmonary Fibrosis.
David J Lederer, Fernando J Martinez. N Engl J Med 2018
538
11

Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA.
Imre Noth, David Oelberg, Manika Kaul, Craig S Conoscenti, Ganesh Raghu. Eur Respir J 2018
19
57

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.
Bruno Crestani, John T Huggins, Mitchell Kaye, Ulrich Costabel, Ian Glaspole, Takashi Ogura, Jin Woo Song, Wibke Stansen, Manuel Quaresma, Susanne Stowasser,[...]. Lancet Respir Med 2019
84
13

Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.
Martin Kolb, Ganesh Raghu, Athol U Wells, Jürgen Behr, Luca Richeldi, Birgit Schinzel, Manuel Quaresma, Susanne Stowasser, Fernando J Martinez. N Engl J Med 2018
112
11

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study.
Vincent Cottin, Dirk Koschel, Andreas Günther, Carlo Albera, Arata Azuma, C Magnus Sköld, Sara Tomassetti, Philip Hormel, John L Stauffer, Indiana Strombom,[...]. ERJ Open Res 2018
44
25

Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11.
Ganesh Raghu, Shih-Yin Chen, Wei-Shi Yeh, Brad Maroni, Qian Li, Yuan-Chi Lee, Harold R Collard. Lancet Respir Med 2014
332
10

Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis.
Takashi Ogura, Hiroyuki Taniguchi, Arata Azuma, Yoshikazu Inoue, Yasuhiro Kondoh, Yoshinori Hasegawa, Masashi Bando, Shinji Abe, Yoshiro Mochizuki, Kingo Chida,[...]. Eur Respir J 2015
115
10

Idiopathic pulmonary fibrosis.
Talmadge E King, Annie Pardo, Moisés Selman. Lancet 2011
10

Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria.
Ganesh Raghu, Athol U Wells, Andrew G Nicholson, Luca Richeldi, Kevin R Flaherty, Florence Le Maulf, Susanne Stowasser, Rozsa Schlenker-Herceg, David M Hansell. Am J Respir Crit Care Med 2017
108
10

Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.
Helen E Jo, Ian Glaspole, Christopher Grainge, Nicole Goh, Peter M A Hopkins, Yuben Moodley, Paul N Reynolds, Sally Chapman, E Haydn Walters, Christopher Zappala,[...]. Eur Respir J 2017
111
10

Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events.
Ulrich Costabel, Elisabeth Bendstrup, Vincent Cottin, Pieter Dewint, Jim J J Egan, James Ferguson, Richard Groves, Per M Hellström, Michael Kreuter, Toby M Maher,[...]. Adv Ther 2014
83
12

Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece.
Argyrios Tzouvelekis, Theodoros Karampitsakos, Paschalis Ntolios, Vasilios Tzilas, Evangelos Bouros, Evangelos Markozannes, Ioanna Malliou, Aris Anagnostopoulos, Andreas Granitsas, Paschalis Steiropoulos,[...]. Front Med (Lausanne) 2017
32
31

Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study in Greece.
Argyrios Tzouvelekis, Theodoros Karampitsakos, Maria Kontou, Andreas Granitsas, Ioanna Malliou, Aris Anagnostopoulos, Paschalis Ntolios, Vasilios Tzilas, Evangelos Bouros, Paschalis Steiropoulos,[...]. Pulm Pharmacol Ther 2018
35
28

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
Carlo Vancheri, Michael Kreuter, Luca Richeldi, Christopher J Ryerson, Dominique Valeyre, Jan C Grutters, Sabrina Wiebe, Wibke Stansen, Manuel Quaresma, Susanne Stowasser,[...]. Am J Respir Crit Care Med 2018
110
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.